Aura Biosciences has reported positive clinical data from its phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma.
“Ocular melanoma is the most common primary cancer of the eye,” Joe Anderson, CIO of Arix, said in a company news release. “Today, people diagnosed with ocular melanoma are faced with limited treatment options, which often result in vision loss, removal of the eye, and in about half of all cases, metastasis to the liver.”
Aura’s lead program, AU-011, is designed to kill cancer cells in the back of the eye, while leaving surrounding tissue unharmed and preserving patients’ vision. These data indicate that AU-011 has shown good tolerability and signs of vision preservation. We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients. We continue to support Aura as the company progresses towards a pivotal phase 3 study.”
